GeoVax Urges Multisource Mpox Vaccine Strategy Following California Clade 1 Outbreak

The confirmation of locally transmitted Clade 1 mpox cases in Los Angeles County represents a significant escalation in the public health threat facing the United States, with three individuals hospitalized despite having no international travel history according to health authorities (http://www.publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=5161). These cases mark the first known local spread of the more severe Clade 1 strain in the U.S., contrasting with the less severe Clade 2 variant that has circulated since 2022. The development exposes critical vulnerabilities in the nation's vaccine supply infrastructure, particularly the reliance on a single foreign manufacturer for the currently approved MVA-based mpox vaccine.

This dependency creates multiple points of failure in cost management, supply chain security, and surge capacity during escalating outbreaks across Africa, Europe, and now the United States. David Dodd, Chairman & CEO of GeoVax, emphasized the strategic risk, stating that relying on a single overseas manufacturer for critical biosecurity countermeasures represents an unsustainable approach to national health security. The California outbreak serves as a warning signal that America requires a diversified vaccine arsenal incorporating U.S.-based manufacturing and scalable platforms designed for both epidemic response and national stockpiling requirements.

GeoVax's response includes advancing GEO-MVA, their Modified Vaccinia Ankara-based vaccine that has received favorable Scientific Advice from the European Medicines Agency, confirming a streamlined regulatory pathway directly to Phase 3 immuno-bridging trials. This regulatory endorsement accelerates the vaccine's development timeline and strengthens its potential role as a critical additional source MVA vaccine. Simultaneously, the company is progressing a next-generation continuous avian cell line manufacturing platform designed to replace traditional egg-based vaccine production methods.

The manufacturing innovation aims to establish rapid, high-volume U.S.-based production capabilities that would reduce costs, shorten deployment timelines, and reinforce national security. These efforts align with multiple federal initiatives designed to modernize America's pandemic response capabilities, including White House Executive Orders focused on pharmaceutical independence, the HHS-ASPR-DARPA EQUIP-A-Pharma Initiative advancing AI-driven modular manufacturing platforms, and Congressional bipartisan action championed by Senators Joni Ernst and Lisa Blunt Rochester seeking to onshore critical medical manufacturing. The National Security Commission on Emerging Biotechnology has further recommended substantial investment in U.S.-owned biotech infrastructure to address these strategic vulnerabilities.

Dodd noted that these federal initiatives demonstrate serious commitment to pandemic readiness and supply chain security, with GeoVax positioned to respond through their clinically validated MVA platform, EMA-endorsed development plan, and continuous cell line manufacturing strategy. The convergence of emerging public health threats and federal preparedness efforts creates an urgent imperative for developing robust, domestically sourced vaccine alternatives that can respond effectively to evolving infectious disease challenges while ensuring national health security.